论文部分内容阅读
目的对76例复发难治急性髓系白血病(AML)患者治疗结果进行分析,探讨如何进一步提高复发难治AML的缓解率和生存率。方法将近4年收治的复发难治AML36例收为治疗组,而将之前收治30例收为对照组,治疗组采用GEA合用参麦注射液治疗,21d为一疗程;对照组采用大剂量Ara-c治疗,3～5d为一疗程。两组均连用2个疗程无效方确定为无效。结果两组总缓解率比较:治疗组为88.8%,对照组为53.3%,二者差异有统计学意义;两组骨髓抑制时间比较:治疗组中位时间5.5d,对照组中位时间15d,二者差异有统计学意义;两组不良反应及感染率比较:治疗组感染率为25%,对照组为83.3%,二者差异有统计学意义。结论GEA合用参麦注射液方案能明显提高复发难治AML的缓解率,且骨髓抑制时间短,不良反应相对少,感染率明显降低。
Objective To analyze the treatment outcome of 76 patients with relapsed-refractory acute myeloid leukemia (AML) and explore how to further improve the remission rate and survival rate of refractory relapsed AML. Methods The patients with relapsed or refractory AML in the past four years were enrolled as the treatment group, while the patients with the previous treatment of 30 cases were treated as the control group. The treatment group was treated with GEA combined with Shenmai injection for 21 days, while the control group was treated with Ara- c treatment, 3 ~ 5d for a course of treatment. Two groups were treated with two courses of ineffective side was determined to be invalid. Results The total remission rate of the two groups was 88.8% in the treatment group and 53.3% in the control group, with significant difference between the two groups. The comparison of the time of bone marrow suppression between the two groups was: 5.5 days in the treatment group and 15 days in the control group, The difference between the two groups was statistically significant; two groups of adverse reactions and infection rates: the treatment group infection rate was 25%, 83.3% in the control group, the difference was statistically significant. Conclusion The combination of Shenmai injection and GEA can obviously improve the remission rate of refractory relapsed AML. The bone marrow suppression time is short, the adverse reactions are relatively few, and the infection rate is obviously decreased.